Drug Profile
Research programme: adeno-associated virus gene therapy - Tenaya Therapeutics
Latest Information Update: 14 Feb 2022
Price :
$50
*
At a glance
- Originator Tenaya Therapeutics
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiomyopathies
- Research Heart failure
Most Recent Events
- 14 Feb 2022 Early research in Heart failure in USA (unspecified route) (Company pipeline, 14 February 2022)
- 30 Dec 2021 Tenaya Therapeutics has patent protection for methods of enhancing activity of the SERCA pump using the DWORF peptide in USA
- 30 Dec 2021 Tenaya Therapeutics has patents pending for methods of enhancing activity of the SERCA pump using the DWORF peptide in USA